spacer
home > ebr > summer 2018 > natural intelligence looks at ai
PUBLICATIONS
European Biopharmaceutical Review

Natural Intelligence Looks at AI

Artificial intelligence (AI) is the fourth industrial revolution. Machinelearning, Big Data, and basic science have reached a tipping point where the question is not if, but when. Media coverage of AI is abuzz with driverless cars, facial recognition, and data analytics. However, public reception is divided. Is it a positive transformation of the human condition or a brave new world? Nations and industries alike have embraced AI, fearing to be left behind in the race for global competitive advantage.

AI is now being adopted by all the major biopharmaceutical companies at every stage of their pipeline workflows. Industrial and academic research centres and a spate of new startups and investors are all sprinting towards this new reality. Still, the hype and skepticism surrounding biotechnology applications of AI echoes earlier paradigm shifts in the drug discovery high throughput screening, molecular modelling, and rational design. Critics say these never lived up to the promise, yet they continue to play an important role in drug discovery today.

What Is AI?

AI consists of software systems based on the confluence of computing power, large data sets, and models that mimic the understanding of the human brain. They attempt to self-learn from training sets of data and develop the ability to interpret new inputs. They provide reasoned outputs and predictions in new situations. These learning engines are model-free. Cause-and-effect is not as obvious as one might expect in a linear regression or a decision tree. Simultaneously, they achieve a high level of predictive accuracy in datasets that are too large and multidimensional for an individual to handle.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a Chinawatcher, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach combined with therapeutic expertise, regulatory know how, and global presence delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

HPLC 2018

29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA

Are you interested in mass spectrometry, chromatography, or electrophoresis? Are you solving complex analytical problems? Are you looking for a conference with strong scientific content, a robust program, presentations by world renowned experts, lectures by young scientists, courses offering great training opportunities, tutorials, panel discussions, vendor technical workshops, best poster competition, and a major exposition showcasing new product launches and innovative products? Mark your calendar to attend HPLC 2018 Washington, DC, the largest, most recognized international conference in the world devoted to advances in separation technologies!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement